Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.36 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605950 | 0.92 | RAB9A (0.42) | SMN1; SMN2XIAPRAB9ADPP4L3MBTL1 | |
| SCHEMBL3598521 | 0.84 | CTSK (0.46) | KMT2AHDAC8 | |
| SCHEMBL3612571 | 0.81 | DPP4 (0.48) | SMN1; SMN2DPP4 | |
| SCHEMBL27485070 | 0.77 | POLB (0.48) | XIAPKMT2AHDAC8 | |
| SCHEMBL3604870 | 0.77 | POLB (0.48) | XIAPKMT2AHDAC8 | |
| SCHEMBL5696171 | 0.77 | POLB (0.48) | XIAPKMT2AHDAC8 | |
| SCHEMBL5696170 | 0.77 | POLB (0.48) | XIAPKMT2AHDAC8 | |
| SCHEMBL3605952 | 0.76 | POLB (0.46) | XIAPKMT2AHDAC8 | |
| SCHEMBL11341773 | 0.76 | PREP (0.54) | RAB9AL3MBTL1KMT2ACCR1LMNA | |
| SCHEMBL11341775 | 0.76 | PREP (0.54) | RAB9AL3MBTL1KMT2ACCR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
| EP-1919864-A2 | FAP INHIBITORS | Ferring B.V. (NL) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007085895-A2 | FAP INHIBITORS | FERRING B.V. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | SMN1; SMN2 2583/4885XIAP 594/4885RAB9A 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.